Clinical Trials on Refractory Childhood Hodgkin Lymphoma in United States

Total 3345 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | T-Cell Chronic Lymphocytic Leukemia | Recurrent Childhood Non-Hodgkin... and other conditions

United States, Germany
National Cancer Institute (NCI)

Completed

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Recurrent Adult Hodgkin Lymphoma | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Adult Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

Refractory Childhood Hodgkin Lymphoma | Ann Arbor Stage I Childhood Hodgkin Lymphoma | Ann Arbor Stage II Childhood Hodgkin Lymphoma | Ann Arbor Stage III Childhood Hodgkin Lymphoma | Ann Arbor Stage IV Childhood Hodgkin Lymphoma

United States, Canada, Australia, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Lymphocyte Depletion Hodgkin Lymphoma | Childhood Mixed Cellularity Hodgkin Lymphoma | Childhood Nodular Sclerosis Hodgkin Lymphoma | Childhood Favorable Prognosis Hodgkin Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Waldenstrom Macroglobulinemia | Refractory Plasma Cell Myeloma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia and other conditions

United States
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Post-transplant Lymphoproliferative Disorder | Recurrent Childhood Large Cell Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Recurrent Childhood Small Noncleaved Cell Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | AIDS-related Peripheral/Systemic Lymphoma | AIDS-related...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation Recipient

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma | Refractory Childhood Hodgkin Lymphoma | Recurrent Childhood Hodgkin Lymphoma

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
Florida International University
National Institute on Minority Health and Health Disparities (NIMHD); Nicklaus... and other collaborators

Recruiting

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recurrent Childhood Ependymoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Large... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Refractory Aggressive Non-Hodgkin Lymphoma

United States
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
National Cancer Institute (NCI)

Completed

Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Medulloblastoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Leptomeningeal Metastases | Childhood Diffuse Large Cell Lymphoma | Childhood Immunoblastic Large Cell Lymphoma and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Relapsed Adult ALL | Relapsed CLL | Refractory B-Cell Small Lymphocytic Lymphoma

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Recruiting

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). (pediTACTAL)

Hodgkins Lymphoma | Non Hodgkins Lymphoma

United States
Stanford University

Terminated

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Primary Myelofibrosis | Myelofibrosis | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Refractory Non-Hodgkin Lymphoma | Blast... and other conditions

United States
St. Jude Children's Research Hospital
Seagen Inc.

Active, not recruiting

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Refractory Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Florida International University
Nicklaus Children's Hospital f/k/a Miami Children's Hospital

Completed

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

Recurrent Childhood Ependymoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Large... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma and other conditions

United States
Joseph Tuscano
Spectrum Pharmaceuticals, Inc

Active, not recruiting

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Relapsed Non Hodgkin Lymphoma | Refractory Non Hodgkin Lymphoma

United States
Loyola University

Completed

Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

United States
Marker Therapeutics, Inc.

Recruiting

Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO)

Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, Relapsed

United States
National Cancer Institute (NCI)

Terminated

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Intraocular Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides... and other conditions

United States
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
Brian Hill

Recruiting

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Non-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

United States
Adam Kittai

Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Intra-Osseous Co-Transplant of UCB and hMSC

Myelodysplastic Syndromes | Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Lymphoid Malignancies | Relapsed Non-Hodgkin Lymphoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's Lymphoma

United States
Dana-Farber Cancer Institute
HiberCell, Inc.

Completed

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory...

United States
Precision BioSciences, Inc.

Completed

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B-cell Non Hodgkin Lymphoma | Leukemia, Lymphocytic, Chronic | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Chronic Lymphoid Leukemia in Relapse

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Classic Hodgkin Lymphoma | Refractory... and other conditions

United States
Spectrum Pharmaceuticals, Inc

Completed

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

Non-Hodgkins Lymphoma | Tumors | Hodgkins Disease

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
SIRPant Immunotherapeutics, Inc.

Recruiting

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult

United States
University of Washington

Recruiting

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma

United States
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Sumithira Vasu

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma | Refractory Follicular...

United States
ImmunityBio, Inc.

Not yet recruiting

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Non Hodgkin's Lymphoma Refractory/Relapsed

United States
AstraZeneca

Completed

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Relapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins Lymphoma

Italy, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States

Clinical Trials on Refractory Childhood Hodgkin Lymphoma in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations